SCHEMBL170646

SCHEMBL170646

NC(=O)c1ccc2[nH]ccc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.68
AR P10275 1/20 0.61
CTNNB1 P35222 5/20 0.57
WNT3A P56704 5/20 0.57
RAB9A P51151 3/20 0.54
MAPT P10636 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
USP2 O75604 1/20 0.52
GAA P10253 1/20 0.52
ALOX15 P16050 1/20 0.52
RAD51 Q06609 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TUBB4A P04350 1/20 0.51
TUBB P07437 1/20 0.51
TUBA3C P0DPH7 1/20 0.51
TUBA1B P68363 1/20 0.51
TUBA4A P68366 1/20 0.51
TUBB4B P68371 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29540009 1.00 F2 (0.68) F2ARCTNNB1WNT3ARAB9A
SCHEMBL27522161 1.00 F2 (0.68) F2ARCTNNB1WNT3ARAB9A
Hydrochloric Acid SCHEMBL28262778 0.98 F2 (0.66) F2ARCTNNB1WNT3ARAB9A
Hydrochloric Acid SCHEMBL28262780 0.98 F2 (0.66) F2ARCTNNB1WNT3ARAB9A
Hydrochloric Acid SCHEMBL28262753 0.98 F2 (0.66) F2ARCTNNB1WNT3ARAB9A
Hydrochloric Acid SCHEMBL5697710 0.98 F2 (0.66) F2ARCTNNB1WNT3ARAB9A
Hydrochloric Acid SCHEMBL5697721 0.96 F2 (0.64) F2ARCTNNB1WNT3ARAB9A
Hydrochloric Acid SCHEMBL28169258 0.96 F2 (0.64) F2ARCTNNB1WNT3ARAB9A
Hydrochloric Acid SCHEMBL5697719 0.95 F2 (0.62) F2ARCTNNB1WNT3ARAB9A
Formic Acid SCHEMBL27629840 0.93 F2 (0.60) F2ARCTNNB1WNT3ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 WO claimed
US-20240317753-A9 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2024-09-26 US claimed
US-20240270748-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2024-08-15 US claimed
CN-118105493-A Skeletal muscle generation inducer, pharmaceutical composition, kit and application thereof 北京大学 2024-05-31 CN claimed
WO-2023196235-A1 METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES GLAZIER ALAN NEIL (US) 2023-10-12 WO claimed
US-20230310471-A1 METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES GLAZIER ALAN NEIL (US) 2023-10-05 US claimed
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 US claimed
CN-116568303-A Dihydrofuranopyridine derivatives as RHO-kinase inhibitors 奇斯药制品公司 2023-08-08 CN claimed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US claimed
WO-2002064578-A1 BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
EP-1187613-A4 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2002-07-24 EP claimed
EP-1187613-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2002-03-20 EP claimed
CN-1305464-A Heterocyclic compounds and methods to treat cardiac failure and other disorders SCIOS INC (US) 2001-07-25 CN claimed
EP-1080078-A1 HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS SCIOS INC. (US) 2001-03-07 EP claimed
EP-1077699-A1 AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE CENTAUR PHARMACEUTICALS, INC. (US) 2001-02-28 EP claimed
WO-2000076505-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 WO claimed
WO-1999061426-A1 HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS SCIOS INC. (US) 1999-12-02 WO claimed
WO-1999059582-A1 AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE CENTAUR PHARMACEUTICALS, INC. (US) 1999-11-25 WO claimed
CN-1114651-A 3-indolylpiperidine MERCK PATENT GMBH (DE) 1996-01-10 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270748-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 F2 2687/4885AR 2673/4885CTNNB1 709/4885
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER TP53, CD4, MCL1 F2 4360/4885AR 1742/4885CTNNB1 1218/4885
US-20240317753-A9 Tricyclic heterocycles YAP1, TEAD1, TERF2IP F2 2854/4885AR 2964/4885CTNNB1 1049/4885
US-20230174538-A1 Tricyclic heterocycles YAP1, TEAD1, TERF2IP F2 2854/4885AR 2964/4885CTNNB1 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.